Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

6.48
+0.13002.05%
Post-market: 6.480.00000.00%17:46 EDT
Volume:619.44K
Turnover:3.94M
Market Cap:296.25M
PE:-3.91
High:6.53
Open:6.38
Low:6.13
Close:6.35
52wk High:23.40
52wk Low:4.05
Shares:45.72M
Float Shares:40.19M
Volume Ratio:0.44
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6560
EPS(LYR):-1.1490
ROE:-120.15%
ROA:-53.40%
PB:2.82
PE(LYR):-5.64

Loading ...

Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating

MT Newswires Live
·
May 20

Capricor Therapeutics Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
May 14

Capricor Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Capricor Therapeutics Q1 EPS $(0.53) Misses $(0.32) Estimate

Benzinga
·
May 14

Capricor Therapeutics Reports Q1 2025 Results: Revenues Drop to $0, Net Loss Widens to $24.4 Million, EPS at $0.53

Reuters
·
May 14

BRIEF-Capricor Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update

Reuters
·
May 14

Press Release: Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

Dow Jones
·
May 13

BUZZ-Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official

Reuters
·
May 07

Press Release: Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

Dow Jones
·
May 06

Sector Update: Health Care Stocks Lower Monday Afternoon

MT Newswires Live
·
May 06

Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment

MT Newswires Live
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-Airline stocks, Wendy's, Skechers

Reuters
·
May 05

BUZZ-Capricor falls after FDA to hold advisory meeting for cell therapy

Reuters
·
May 05

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

GlobeNewswire
·
Apr 01

Capricor Therapeutics Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
Mar 20

Stock Track | Capricor Therapeutics Soars 6.46% Pre-Market on Strong Q4 Results, Analyst Optimism, and Pipeline Progress

Stock Track
·
Mar 20

Stock Track | Capricor Therapeutics (CAPR) Soars 6.38% Pre-Market on Strong Q4 Results and Analyst Optimism

Stock Track
·
Mar 20

Capricor Therapeutics Q4 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $11.10M Beat $5.68M Estimate

Benzinga
·
Mar 20

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
Mar 20

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Mar 18